fbpx

The opportunity
to cure the COVID-19 pandemic
at the outset, and beyond

A collaboration between
K.I.N Japan,
Pollen Group,
Professor Shmuel Ben-Sasson,
and the Hebrew University of Jerusalem

THE PROBLEM

At present,
COVID-19 treatment is
an outstanding unmet need

Current Solutions are
- Vaccines,
- Antivirals,
- Other Treatments
(ventilators, antibodies, blood plasma transfers, stem cells, & immunosuppressants)

153.9M

Confirmed Cases Worldwide
Feb 2020 – Apr 2021

3.2M

Deaths Worldwide
Feb 2020 – Apr 2021

To the updated info: WHO https://www.who.int.

Our Solution

Providing essential metabolic compensation, reduced by COVID-19, to empower damaged lung tissue and the immune system
The therapeutic agent:
Dietary supplement capsules of a safe natural product. It can be also useful for other lung infections such as the flu, asthma and COPD.

Why Use Our Solution?

Converting the disease from potentially lethal to a mild flu-like illness

A natural substance, on the FDA’s GRAS list, with an outstanding safety profile

An affordable solution for the global population, within a short period of time

Administered orally in a user-friendly form (soft-gel capsules)

A novel multi-purpose drug

The same pathological changes that compromise lung function upon COVID-19 infection also occur in other pulmonary diseases and thus can be cured by our agent.

These diseases include:

Influenza

Asthma

COPD

Cystic Fibrosis

Q & A

Why is our product necessary if there are already approved vaccines on the market?

  • ・Many unknowns still exist regarding the efficacy and compliance of the new vaccines
  • ・Meanwhile, COVID-19 is still around, threatening millions of people worldwide
  • ・Our therapy can be used to treat influenza where no effective vaccine is available
  • ・It is also useful against COVID-19 mutants, other coronaviruses, or any other viral infection of the respiratory tract that might emerge as COVID-19 did

Going to Market

Territories

Israel, North and South America, EU, Japan, China, India

Segment

Upper respiratory infections and other lung diseases

Pilot Location

Israel

Our Competitive Edge

  • Preventive medicine (cutting off the pandemic at the outset)
  • Absolutely safe (our own body’s metabolites)
  • Broad-spectrum potential beyond COVID-19 (e.g. flu, asthma, COPD, etc.)
  • Scalable in a short time to provide therapy for hundreds of millions
  • None of the drugs now in development has such a myriad of merits

The Opportunities COVID-19 Opens

  • Approval via fast-track regulatory path for new therapies
  • Generous governmental funding for such novel COVID-19 therapy (non-dilutive financing of companies)

Our Status

Provisional patent application was filed (USA)

Approved for testing against COVID-19 by the Israeli Ministry of Health

Clinical trial approval by Hadassah Medical Center IRB (= Helsinki Committee)

A signed agreement with Kupat Holim Meuhedet, Israel's third-largest health insurance and medical services organization

A signed agreement with Catalent, a leader in drug delivery technologies and manufacturing

Inventor and lead scientist

Prof. Muli Ben-Sasson

CTO

Inventor of the TUNEL assay for apoptosis.

Former chairman of  the Department of Experimental Medicine & Cancer Research at The Hebrew University-  Hadassah Medical School. He also served as visiting professor at Harvard Medical School  for 10 years, where he worked in close collaboration with key opinion leaders in the field  of angiogenesis, including Prof. Judah Folkman of the Surgical Research Dept., Children’s  Hospital (Boston).

Advisory Board

Prof. Aaron Ciechanover

A biologist and physician who shared the 2004 Nobel Prize in Chemistry

Prof. Aaron Ciechanover is an Israeli physician and biologist, who shared the 2004 Nobel  Prize in Chemistry for characterizing the pathway that cells use to degrade and recycle  faulty proteins using ubiquitin. He is currently a Technion Distinguished Research Professor in  the Ruth and Bruce Rappaport Faculty of Medicine and Research Institute at the Technion-  Israel Institute of Technology, in Haifa, Israel. He also shared the 2000 Albert Lasker Award  for Basic Medical Research (regarded as the 2nd most important recognition after the  Nobel) and received the 2003 Israel Prize in Biology. He is a member – among many  esteemed bodies- of the Israeli Academy of Sciences and Humanities, the Pontifical  Academy of Sciences of the Vatican, and a Foreign Associate of the US National Academies  of Sciences (NAS) and Medicine (NAM).

Prof. Zvi Fridlender

Head, Center for COPD & smoking damage, Head Laboratory of lung cancer research

Hadassah Medical Center. Senior  physician in Internal Medicine & Fellow in Pulmonology.  Research fellow in the laboratory of Clinical Immunology (Prof Y. Naparstek) and in the  laboratory of Lung Biology (Prof. R. Breuer). Former research assistant of Prof. T. Peretz,  Head, Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem.

Prof. Eran Bacharach

Head of a research lab for molecular virology at the Department of Cell Research and Immunology

He teaches courses on microbiology,  molecular virology and cell biology at the Faculty of Life Sciences, where he has been on the  faculty since 2000. He received his B.Sc., M.Sc. and Ph.D. degrees from the Hebrew University  and conducted his postdoctoral research at the laboratory of Prof. Stephen P. Goff,  Department of Biochemistry and Molecular Biophysics, Howard Hughes Medical Institute,  Columbia University.

Prof. Reuven Or

Founder of the cancer immunotherapy and immunobiology research laboratories at Hadassah Medical Center.

Prof. Reuven Or was the first to  introduce the use of medical cannabis at the department of bone marrow transplantation  for hospitalized children and adults. Prof. Reuven Or has enjoyed a long and successful  scientific and clinical career and is also a member of the Multidisciplinary Center for  Cannabinoid Research.

Management Team

Assaf Bivas

Chief Executive Officer Co-Founder

Asaf Ofer

COO & Co-Founder

Ofer Shapira

CFO

a CPA with thirty years of financial and business experience and owner of Shapira-Steinberg, a leading CPA firm.

Served as a financial and  operational manager at JVP VC group, a leader venture capital group in Israel. He is  a board member of Bakehila, a leading non-profit organization that helps 3,000  children in Israel every year.

Japan Exclusive Representative

Yaron Mishly

Founder & CEO

Rie Okada

Chief Operating Officer

Ohad Elharar

Region coordinator manager at K.I.N

Scientific Background

Coronaviruses are known to compromise mitochondrial function upon cell infection.  Also, several different studies indicate that there is a significant depletion of cellular  Acetyl-CoA following coronavirus infection. Acetyl-CoA, produced by mitochondria,  plays a pivotal role in maintaining the integrity of lung tissue. Such infection can  therefore lead to rapid deterioration of lung structure and function unless the cells are  able to compensate for the decrease in Acetyl-CoA via up regulation of their  mitochondrial biosynthesis. While such compensation may occur in young people, the  progressively malfunctioning mitochondria of the aging population often fail to adjust.

IP Suite

  • Provisional patent application was filed on May 5, 2020 (USA)
  • Covers a broad spectrum of applications related to breathing problems and lung diseases
  • In addition to oral administration, the IP protects intravenous formulations and a preparation suitable for inhalation

IP Report Conclusions

Coronaviruses are known to compromise mitochondrial function upon cell infection.  Also, several different studies indicate that there is a significant depletion of cellular  Acetyl-CoA following coronavirus infection. Acetyl-CoA, produced by mitochondria,  plays a pivotal role in maintaining the integrity of lung tissue. Such infection can  therefore lead to rapid deterioration of lung structure and function unless the cells are  able to compensate for the decrease in Acetyl-CoA via up regulation of their  mitochondrial biosynthesis. While such compensation may occur in young people, the  progressively malfunctioning mitochondria of the aging population often fail to adjust.

Report prepared by: Dr. Gilad Luria and Dr. Joe Wyse; Head of Patent Department, Patent Attorney.

http://www.bressler.co.il/

If successful, it will constitute a comprehensive solution for the global epidemic of COVID-19 and probably also for influenza, asthma and COPD.

Once a person has started having symptoms, he/she will just have to take it, and will recover within a week or so.

株式会社ケーアイエヌ

K.I.N Co.,Ltd.
Kyoto International Network

TEL +81-75-468-8494
TEL +81-3-5332-7575
FAX +81-75-320-1305

Inquary




Copyright © K.I.N Co.,Ltd.  All Rights Reserved.